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SUMMARY 
 Background: Pemphigus vulgaris (PV) is an autoimmune disease characterized by 
mucocutaneous intraepithelial blisters and pathogenic autoantibodies against 
desmoglein 3. There are two clinical forms: mucosal (MPV) and mucocutaneous 
(MCPV). The frequency of ear, nose and throat (ENT) involvement in PV is not clearly 
defined. Only a few isolated individual cases have been reported. 
Objectives: The objective of our study was to determine the incidence of ENT 
involvement in patients with PV. 
Patients: We studied prospectively all 16 patients diagnosed with PV and treated in the 
Department of Dermatology of the University Clinic of Navarra between 2001 and 
2005. They were 10 cases of MPV and six cases of MCPV. All patients were evaluated 
for ENT manifestations by endoscopic examination. 
Results: Of the 16 patients, 13 presented with throat symptoms (81%), 12 pharyngeal 
(75%) and seven laryngeal symptoms (44%). Fourteen patients (88%) had active PV 
lesions on endoscopic evaluation (eight patients had active lesions on both pharyngeal 
and laryngeal mucosa, four had PV lesions only on laryngeal mucosa and two had PV 
lesions on pharyngeal mucosa). Laryngeal lesions were most commonly present in 
MPV patients. The frequency of nasal symptoms (38%) was lower than active PV 
lesions (62%) found on ENT examination. Oral symptoms and oral active PV lesions 
were the most frequent findings (94%). Only three patients with MCPV showed 
erosions on the external auditory canal. Conclusions As ENT endoscopy allows more 
extensive areas of mucosa to be examined than simple visual inspection, we recommend 
that it be included in the examination of all patients with PV. By obtaining more 
complete information concerning the extent of the disease, a more accurate diagnosis 
can be made, better choice of drug and dose may be decided and, ultimately, response to 
treatment may be improved. 
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Pemphigus vulgaris (PV) is an autoimmune bullous disease, characterized by the 
development of acantholysis on the skin and/or mucosa secondary to IgG antibody 
synthesis against a desmosomal glycoprotein, desmoglein (Dsg), present in kera-
tinocytes.1 Two clinical subtypes of PV have been defined. The mucosal form of PV 
(MPV) is characterized by a predominant anti-Dsg3 autoimmune response. In contrast, 
the mucocutaneous form (MCPV) shows a combined anti-Dsg3 and anti-Dsg1 
autoantibody response, the patients’ mucosa is affected and over five skin lesions are 
present.2 The frequency of ear, nose and throat (ENT) involvement in PV is not known. 
Only a few isolated individual cases have been reported,3–17 most published in ENT 
journals. Recently, Hale and Bystryn18 described laryngeal and nasal findings in 53 
patients with PV, although only 11 underwent ENT examination. In the present report, 
ENT manifestations in 16 patients with PV, examined by ENT endoscopy, are 
presented. 
 
 
PATIENTS AND METHODS 
This prospective study includes 16 sequential patients with PV, 10 cases of MPV and 
six of MCPV. All attended the Department of Dermatology of the University Clinic of 
Navarra between 2001 and 2005. Criteria used for diagnosis of PV are described 
elsewhere.2 Briefly, patients with MPV showed predominant oral erosions with limited 
skin involvement, fewer than five or six scattered or isolated erosions or blisters, and 
each <5 cm in diameter. Patients with MCPV showed extensive skin involvement in 
addition to oral involvement. If more than six erosions or blisters >5 cm in diameter 
were present on the skin, the patient was considered to have the mucocutaneous type of 
PV.2 If patients meeting the mucosaltype criteria had positive anti-Dsg1 and anti-Dsg3 
antibodies, these cases were considered to have mucosal-dominant PV, as has been 
established by other authors.19 Initial symptoms and clinical lesions in our patients had 
been observed for between 1 and 60 months before the patient came to our department 
for the first medical visit (Table 1). In all patients the treatment consisted of high doses 
of corticosteroids (0.3–1 mg kg-1 daily), together with immunosuppressive drugs 
(azathioprine 1–1.5 mg kg-1 daily or mycophenolate mofetil 3 g daily). Only patient 1 
had not been treated before coming to our department. The dose of corticosteroids and 
immunosuppressive treatment was adjusted at each follow-up visit based on the 
cutaneous and mucosal manifestations of PV, and the mucosal involvement observed by 
ENT endoscopy. 
All patients were evaluated for ENT manifestations by endoscopic examination at the 
first medical visit to our hospital, whether or not they had symptoms. All ENT 
examinations were carried out by one of the authors (S.F.). After the first ENT 
examination, each patient was evaluated by endoscopic examination at subsequent 
follow-up visits only when ENT symptoms were persistent or active PV lesions had 
been observed in the previous ENT examination. ENT examination was also carried out 
when a patient had a new flare of PV lesions. As a result, the number of ENT 
examinations was different for each patient. Mucosal cultures were taken in those 
patients in whom a bacterial, viral or fungal mucosal infection was suspected. If patients 
had previously been evaluated in other hospitals, and had already presented with ENT 
symptoms or clinical lesions related to PV, or had undergone previous ENT endoscopy, 
that information was always included in their medical records. Table 1 includes 
complete clinical and serological information for each patient. Table 2 shows the 
complete symptomatology presented by our 16 patients from the beginning of their 
mucosal and skin manifestations. 
 
 
RESULTS 
Oral symptoms and active oral PV lesions were the most frequent findings in our study. 
The oral symptoms reported were pain or stinging in the oral cavity (94% of all the 
patients with PV) (Table 2). To date, only one patient with MCPV has not had active 
oral mucosal lesions at some time during the course of the disease (Table 1). Oral 
symptoms appeared at the beginning of the clinical manifestations of PV. 
Of the 16 patients with PV, 13 presented with throat symptoms (81%) (either 
pharyngeal or laryngeal symptoms, or both), but 14 (88%) had active PV lesions as 
determined by endoscopic evaluation (Table 1). Symptoms affecting the pharyngeal 
mucosa most often manifested as tenderness in the throat or pain on swallowing; these 
symptoms occurred in 12 patients (75% of all the patients with PV, both symptoms) 
(Table 2). Symptoms related to the laryngeal mucosa were reported by seven patients 
(44%), including hoarseness and/or dysphonia (31% and 44%, respectively) (Table 2). 
These symptoms appeared when PV first occurred, and when some patients experienced 
a flare of their symptoms including new blisters and erosions on skin and/or mucosa. 
Overall, 12 patients presented with active lesions on the laryngeal mucosa (75% of the 
patients with PV) and 10 patients presented with active lesions on the pharyngeal 
mucosa (62% of PV patients); eight patients had active PV lesions on both pharyngeal 
and laryngeal mucosa, four had PV lesions only on the laryngeal mucosa, and two 
patients had erosions only on the pharyngeal mucosa (Table 1). Surprisingly, while all 
patients with MPV presented with laryngeal lesions (100% of patients with MPV), this 
was the case with only two of the patients with MCPV (33% of patients with MCPV) 
(Table 1). However, the frequency of active erosions on pharyngeal mucosa was similar 
in patients with either MCPV or MPV (60% and 67%, respectively) (Table 1). 
Of all the 16 patients with PV, only six had nasal symptoms (38%). However, 10 cases 
(62%) presented with active mucosal PV lesions, such as crusting and erosions, on ENT 
examination (Table 1). Six of these 10 cases had MPV (60% of the patients with MPV) 
and four had MCPV (67% of patients with MCPV). Nasal symptoms appeared at the 
beginning of the mucocutaneous disease, or with flares of PV. The symptoms reported 
were epistaxis (38%), presence of a blood-tinged mucus (19%) or stuffiness (25%) 
(Table 2). 
Ear symptoms were the least frequent symptom and clinical finding in the 16 patients 
with PV. All three patients with ear symptoms presented with pain and ear canal 
obstruction (Table 2). Ear symptoms appeared when the patients had a flare of PV 
lesions. These symptoms followed an evolution similar to that of skin lesions after 
administration of corticosteroids and immunosuppressive drugs. These three patients 
had MCPV. No ear lesions were observed in patients with MPV. 
In some patients, active lesions were found on mucosae other than those of the ear, nose 
or throat. These included anal (patients 3 and 13), genital (patients 1, 3, 5 and 7) and 
conjunctival mucosae (patients 5, 7 and 13). 
Some patients were asymptomatic for pharyngeal, laryngeal or nasal symptoms despite 
active lesions demonstrated by endoscopy (e.g. patients 4, 5, 7, 8 and 10). Those 
patients with more extensive mucosal active PV lesions received higher doses of 
corticosteroids and were treated for longer than those patients with fewer mucosal PV 
manifestations. 
In several patients ENT symptoms could have been due to mucosal inflammation, as six 
cases had cultures positive for Staphylococcus aureus on nasal mucosa, and five patients 
had cultures positive for Candida spp. (Table 1). These patients were treated with 
antibiotics and anticandidal therapy, along with corticosteroids and immunosuppressive 
drugs. 
 
 
DISCUSSION 
This study reveals that a high number of patients with PV may present with active ENT 
lesions. Therefore, all dermatologists should be aware of which ENT manifestations 
might be present in patients with PV at some time during the course of this disease. 
Most of the data related to ENT manifestations in PV have been in reports of individual 
cases.3–17 However, Hale and Bystryn18 described laryngeal and/or nasal findings in 53 
patients with PV, although only 11 underwent ENT examination. Our study underlines 
the importance of exploring ENT mucosa by endoscopic techniques in all patients with 
PV, in order to determine the real extent of active PV lesions. Overall, all of our patients 
except one (patient 16) had some active erosions on ENT mucosa together with one or 
more symptoms. However, individual symptoms were missing in some patients where 
erosions were found (Table 1). Also, our findings show that ENT manifestations in 
patients with PV are not in fact associated with a more aggressive form of PV. Indeed, 
most of our patients presented a mucosal form with active lesions apparently localized 
only on the oral mucosa (Table 1). 
Although many patients may experience ENT symptoms during their disease, our study 
shows that the presence of active lesions on mucosal surfaces may be more extensive 
than was originally thought. This difference between symptoms and clinical findings by 
ENT examinations was most striking in the nasal cavity. Nasal symptoms were reported 
in 38% of patients (mainly epistaxis and stuffiness) (Table 2), but erosions and crusting 
on nasal mucosa were detected in 62% of cases. Patients with MPV usually reported no 
discomfort in the nasal fossa, but ENT examination frequently revealed erosions and 
crusting (Table 1). In contrast, all the patients with MCPV with nasal symptoms also 
presented active PV lesions on the nasal mucosa by ENT examination (Table 1). Hale 
and Bystryn reported nasal symptoms in 23% of their patients, but ENT evaluation was 
recommended only in four, and active nasal PV lesions were found in only three.18 
These authors noted, as was also the case in our study, that these symptoms were 
usually related to a flare of PV. Of the six patients with cultures positive for S. aureus 
on nasal mucosa in our study, only three had some discomfort in the nasal fossa. 
Perhaps the role of these bacteria in the presentation of nasal symptoms was minor in 
our patients. 
The most surprising findings in this study were related to laryngeal manifestations. Only 
44% of patients presented with symptoms associated with the larynx, mainly hoarseness 
and dysphonia (Table 2). However, 75% had active PV lesions on the laryngeal mucosa 
on ENT examination. Even more interesting is the fact that these lesions were found 
mostly in patients with MPV. Only two patients with MCPV had lesions on this mucosa 
(Table 1). Hale and Bystryn18 found laryngeal symptoms in 40% of patients with PV. 
Only seven of these patients had an ENT evaluation, and active laryngeal lesions were 
found in four of them. The difference between laryngeal symptoms and the findings of 
active PV lesions may be related to the area of larynx affected. Only erosions on the 
vocal folds produced dysphonia or hoarseness, while active lesions on the epiglottis 
produced tenderness in the throat or pain on swallowing. We do not know the reason for 
the high frequency of active laryngeal lesions almost exclusively in patients with MPV. 
In general, this kind of PV symptom is associated with a flare of PV lesions. On the 
other hand, Candida spp. infection on the laryngeal mucosa could contribute to 
hoarseness in our patients, as has been established by other authors.7 Both symptoms 
and infection of Candida spp. were more prevalent in patients with MPV. As yet, we 
can offer no reason for these findings. 
There are some data in the dermatological literature related to ear involvement in PV.13 
Our study found only three patients showing erosions in the auricle and auditory canal 
of the ear. All three patients presented with MCPV. These findings may reflect one 
more characteristic clinical manifestation of MCPV. 
Our findings show that the management of PV must be an interdisciplinary process. 
ENT manifestations should be examined by an ENT specialist with experience of PV 
patients, and endoscopic techniques should be used. Other diagnoses to be considered 
when using direct fibroendoscopy are Wegener’s granulomatosis, blistering mucosal 
disease, such as cicatricial pemphigoid, or nonspecific membranous mucositis. Further-
more, ENT endoscopy may be useful for obtaining additional information related to the 
viral, bacterial or fungal agents causing the infection on the inflamed mucosa in patients 
with PV. 
In summary, ENT endoscopy allows more extensive areas of mucosa to be examined 
than simple visual inspection. Consequently, we recommend that it be included in the 
examination of all patients with PV. By obtaining more complete information 
concerning the extent of the disease, a more accurate diagnosis can be made, a better 
choice of drug and dose may be decided and, ultimately, response to treatment may be 
improved. 
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Table 1. Clinical and ear, nose and throat (ENT) manifestations in 16 patients with 
pemphigus vulgaris (PV) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Frequency of ear, nose and throat symptoms in 16 patients with 
pemphigus vulgaris 
 Frequency of symptoms 
Symptoms Number of patients % 
Throat 13 81 
Pharyngeal mucosa 12 75 
Tenderness 12 75 
Pain on swallowing 12 75 
Laryngeal mucosa 7 44 
Hoarseness 5 31 
Dysphonia 7 44 
Nasal mucosa 6 38 
Epistaxis 6 38 
Blood-tinged mucus 3 19 
Stuffiness 4 25 
Ear 3 19 
Pain 3 19 
Ear canal obstruction 3 19 
Oral 15 94 
Pain 15 94 
Stinging 15 94 
 
 
